Zhongtian Medical Submits IPO Prospectus Highlighting Its AIS One-Stop Innovative Solution

Acute ischemic stroke (AIS) is the most common type of stroke, characterized by sudden onset and rapid progression. It is the leading cause of mortality and disability in China. Endovascular therapy has become the first-line treatment for acute ischemic stroke.

As Shenjie continues to launch high-quality products, providing physicians with a broader arsenal of tools, the selection of medical devices has become a new challenge. From Tianyi^®From the Tianxun™ navigational microcatheter for stent retrievers to MicroPort NeuroTech’s one-stop innovative product portfolio for Acute Ischemic Stroke (AIS), the successive launch of these products is a testament to the fruits of innovation. In just a few years, MicroPort NeuroTech has achieved leapfrog development, evolving from a single-product manufacturer to a provider of comprehensive, one-stop AIS solutions. Furthermore, through collaboration with Chinese physicians, MicroPort NeuroTech has transformed their clinical insights into high-quality products that match or even surpass the performance of those offered by leading international manufacturers.

VCBeat Selects New Product Review Issue 17 Invites Xia Jie, Chairman and CEO of Zhongtian Medical; Chen Chong, Sales and Marketing Director of Zhongtian Medical; and Yang Bin from Xuanwu Hospital to Present Zhongtian Medical’s Products.

AIS One-Stop Innovative Solution: Easier Product Selection, Less Effort in Surgery, and Safer Patient Care.

Improvement:The Tianxun Tonglu Family of Products Has Been Fully Assembled

Peers:Aspiration Catheter: Matching the Quality and Performance of Leading International Products

Iteration:Tianyi Thrombectomy Stent: The World’s First Pull-Back Self-Rotating Design Leads the 4.0 Era of Thrombectomy Devices

Innovation:“Medical-Enterprise Innovation” Product Navigation: Microcatheters Reduce Surgical Complexity, Making Procedures Simpler, Faster, and Safer

Viewing Method: Scan the QR code on the poster below to add our assistant and reserve your spot for the live broadcast.

Xia Jie

Chairman and CEO of Zhongtian Medical

Graduated from Capital Medical University with a major in Clinical Medicine, and previously worked at Peking University First Hospital.

Master’s degree from California State University, Long Beach; previously employed at Abbott Northwestern Hospital

6 years of clinical experience, over 20 years of R&D and commercialization experience in medical devices

Founded U.S.-based company AQURE Medical, completing the R&D and FDA registration of the world’s first dual-lumen catheter.

Named a Science and Technology Leader in Suzhou Industrial Park, and one of the first batch of Gusu Innovation and Entrepreneurship Leading Talents

Chen Chong

Director and Sales & Marketing Director, Zhongtian Medical

Shanghai Jiao Tong University, EMBA

Formerly served as Regional Manager of the Eastern Region at Hongyi Medical.

W. L. Gore & Associates, Regional Manager, East China

Boston Scientific, Sales Manager, Peripheral Intervention Division

MicroVention, National Sales Director

15+ Years of Sales and Marketing Experience in Vascular Intervention

Yang Bin

Chief Physician, Xuanwu Hospital of Capital Medical University

Chief Physician, M.D. in Clinical Medicine; completed postdoctoral research under the supervision of Professor Ling Feng, a renowned neurosurgery expert.

Vice Chairman of the Neurointervention Branch of the Beijing Society of Neurology, and Member of the Surgical Professional Committee on Ischemic Stroke under the Brain Prevention and Control Commission of the National Health Commission.

Clinically specializes in stent angioplasty for intracranial and extracranial arterial stenosis, mechanical thrombectomy for acute ischemic stroke, and carotid endarterectomy, with an annual surgical volume exceeding 300 cases. Principal investigator of one neurointerventional research project sponsored by the Capacity Building and Continuing Education Center of the National Health Commission; participated in six national and provincial-level research projects, including those funded by the National Natural Science Foundation of China, the National Key R&D Program, and the Beijing Municipal Science & Technology Project. Authored more than 10 peer-reviewed articles published in journals such as Neurology, Journal of NeuroInterventional Surgery (JNIS), and Translational Stroke Research, eight of which are indexed in SCI; also contributed to one translated medical monograph.

Zhongtian Medical, established in 2018, is a modern technology-driven medical device enterprise integrating research and development, manufacturing, and sales, dedicated to becoming a provider of innovative solutions for vascular diseases.

Over the past five years, Zhongtian Medical has developed a series of “innovative, high-quality” vascular interventional products targeting pan-vascular diseases, guided by clinical pain points and needs. The company has currently obtained 11 product registration certificates, establishing a competitive advantage with its AIS (Acute Ischemic Stroke) one-stop innovative solution characterized by “comprehensive aspiration capabilities, complete access solutions, and innovation-driven enhancements.” By the end of 2023, it will have accumulated 15 product registration certificates and officially launched overseas market promotion. Meanwhile, in the field of carotid and intracranial stenosis treatment, Zhongtian Medical has completed the R&D and clinical stages for multiple implantable products featuring international-level innovations.

“Artery Select New Product Launch” is a live-streaming program under the “Artery Select” brand, dedicated to supporting medical enterprises in launching innovative products. The program’s mission is: to empower the milestone launch of every innovative medical product.

Scan the QR code above to contact the assistant and schedule a live broadcast.

(If already added, please proactively contact the assistant.)